Presented by
Management Forum

Dry Powder Inhalers

A comprehensive overview of DPIs including market trends, treatments formulation, regulation and device design *FULLY UPDATED PROGRAMME*

28-29 Jun 2022 + 1 more date

Enrol now

  • Format: Live online, Classroom
  • CPD: 12 hours for your records
  • Certificate of completion

Conference overview

The global dry powder inhaler (DPI) market is expected to grow at a robust rate over the next few years. The growing prevalence worldwide of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is one of the major factors fuelling this growth with a rising demand for advance healthcare devices for the treatment of these chronic diseases.

This annual two-day seminar will provide a comprehensive review of all the key aspects of DPIs including therapeutic targets, the latest delivery technologies and the current regulatory landscape. Participants will gain a valuable insight into market potential, respiratory diseases and key treatment guidelines, formulation, stability testing, characterisation studies, device design, human factors, quality by design (QbD) and the manufacturing process. Intellectual property, bioequivalence and the opportunities of connectivity with DPIs will also be addressed.
This must-attend event will include practical workshop sessions and provide a unique opportunity to discuss DPIs with fellow professionals and our expert faculty of speakers who all have significant expertise in this field.

Benefits of attending:
  • Know the market potential
  • Clarify the therapeutic targets
  • Gain an insight into delivery technologies
  • Consider key treatment guidelines
  • Understand the formulation challenges
  • Discuss essential aspects of DPI QbD medicine development
  • Obtain key information on device design and human factors
  • Know the regulatory pathways to follow
  • Consider bioquivalence (in-vitro vs in-vivo)
  • Consolidate learning with interactive workshops and discussion sessions

Media Partners

Inhalationlogo

RDDEurope2019

Who should attend

This event will be beneficial to all those new to the area and those who require a refresher on the opportunities and challenges with this technology. The content will appeal to pharmaceutical scientists, formulation scientists and analysts, device designers and specialists in industrialisation, quality assurance and regulatory affairs who may want to gain an understanding of both the history of and current practices in DPI development and manufacture in the pharmaceutical industry. It will be of benefit to individuals with an interest both in innovative and generic products and the associated international regulatory expectations associated with DPI products.

Professionals from associated industries such as primary packing suppliers, excipient (used in DPIs) producers, DPI equipment designers and manufacturers for unit processes who wish to understand the scope of DPI respiratory medicine development will also find this seminar useful.

Media partners and exhibitors

 

Media partners


 

Exhibitors

 

Enrol now

The Dry Powder Inhalers course will cover:

Markets and trends for respiratory medicines (MDIs, nebulisers, DPIs)

  • Global overview
  • Developed vs emerging markets
  • Cost – value – price
  • Environmental impacts – a new opportunity?
  • NICE guidance on using DPIs
  • Changes in therapies

Respiratory diseases/treatments/guidelines

  • Asthma
  • COPD
  • Other lung diseases
  • Treatments and medicines
    • Ancient and new
  • Lung disease treatment guidelines
    • Global Initiative for Asthma (GINA)
    • Global Initiative for Chronic Obstructive Lung Disease (GOLD)

Aim of formulating respiratory medicines

  • Single and multi-dose systems
  • The patient – human factors engineering (HFE)
  • Manufacturing processes and systems
    • DPI unit processes

Device design

  • General principles (historic)
  • The optimum design process
  • Considerations
  • The role of design control (ISO and CFR)
  • Innovation vs generic approaches
  • What documentation do I need?
  • Materials strategies
  • A global approach

Medicine testing/stability/ characterisation studies

  • DPI testing
    • Aerodynamic particle size distribution (APSD) etc
  • Stability (regional vs global strategy)
  • Characterisation studies
  • Bioequivalence (in-vitro vs in-vivo)

WORKSHOP ONE: Device Design

DPI QbD medicine development

  • Quality target product profile (QTPP)
  • Critical quality attributes (CQAs)
  • Critical process parameters (CPPs)
  • Developing control strategy

Regulatory requirements and considerations

  • Combination product initiatives
  • MDD vs MDR
  • Usability/human factors (US vs EU)
  • CTD changes
  • New (!) guidances
  • Current best practice
  • Communication approaches
  • Risk management
  • Post-market activity (device)

WORKSHOP TWO: Quality by design

Intellectual property

  • Overview of the landscape
  • When, what and how
  • Novelty vs infringement vs obviousness
  • The concepts of soft and hard IP
  • Resources

Connected medicine

  • Current DPI products
  • Fact or fiction
  • Unique selling points (USPs)

Enrol now

Mike Holroyd

Mike Holroyd is Senior Director with responsibility for the design, development and scale-up of inhalation devices within the Mylan Global Respiratory Group. He has an MA in Engineering from St. Catharine’s College, Cambridge. He started his career at Rolls-Royce Aero engines, before moving to PA consulting group where he was a Partner and manager of the product development group. He then joined Norton Healthcare in 1993, where he directed all inhalation device development, including engineering, formulation development and analytical laboratory services and the subcontract manufacture of devices. At Norton he developed, scaled-up and launched Easi-Breathe as well as developing the Spiromax MDPI. He was awarded the Royal Academy of Engineering MacRobert award for the development of Easi-Breathe.
He left Noton (now part of IVAX) to start his own consultancy business, before joining Phoqus Pharmaceuticals as Vice President Engineering to develop novel drug delivery systems based on electrostatic deposition technology. He then returned to consultancy, operating as Programme Director on a major new respiratory device development, until he joined Myland in 2013.

More details

David Howlett

In 2003 David established PharmaDelivery Solutions Ltd as a specialised consultancy service in the field of drug delivery combination products (especially respiratory) device technology. This has led to involvement in projects with focus in pulmonary, nasal and other delivery routes, with an international client base. Much of the activity of PharmaDelivery Solutions Ltd is focused in the area of development programme support, regulatory GAP analysis and generation of documentation supporting development and test programmes, together with data review and contingency evaluation.

David has over 35 years experience in the development, industrialization and approval of inhalation drug delivery systems, combination products and medical devices.

PharmaDelivery Solutions Ltd has provided input ranging from GAP analysis and comment to complete remedial implementation in areas including

• Design Control
• Risk Management
• Materials strategies
• Regulatory documentation
• Technical reviews and opinion

In addition to activities supporting commercial organizations, David has been involved in the following roles;

Honorary Teaching Fellow in the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester and is author/ tutor for the Pharmaceutical Industry Advanced Training (PIAT) MSc module on Inhalation dosage forms.

A UK national expert representing the British Standards Institute on ISO TC84 developing new international standards for pulmonary and nasal delivery devices syringes and catheters.

David has also worked with the United Nations and various national governments to develop and establish transition strategies from the use of CFC in Metered Dose Inhalers and to secure appropriate budgets from the Multi-lateral fun for the implementation of the Montreal Protocol in emerging markets around the world.

More details

Helen Muirhead

Helen now is an independent Respiratory Medicine Expert, acting as a consultant after 30 years with GSK in both R&D and Manufacturing. Helen is also now involved in teaching at Universities and supports Lung Disease charities.

In GSK, Helen headed up the Respiratory Centre of Excellence during the late stages of Product Development through Regulatory Filing and Commercial Launch and supply of new Medicines – in the Ellipta Portfolio (Including the recent Trelegy, triple drug therapy). Helen was also responsible for the classic and establish brands; the existing Diskus Portfolio (Including Advair).

Helen and her team were based in Ware (UK), Evreux (France) and Zebulon (USA): it comprised of Pharmacists, Chemists, Material Scientists, Engineers and Device designers and she was Accountable for the robustness and reliability of the Respiratory Products and Processes, as well as the skills and competency of the Global Respiratory Technical Organisation.

Helen was also the Technical Lead on the Global Ellipta and Diskus Manufacturing Excellence Forums.

A Fellow of the Royal Society of Chemistry, with 42 years of Industrial experience from Quality Control, Quality Assurance, Analytical method development, including 15 years in R&D Respiratory Product Development (in pMDIs and DPIs development), through Clinical Trials Design and manufacturing… heading up the Respiratory Pilot Plant. Helen has been in Technical roles within Manufacturing for 15 years.

More details

Book Dry Powder Inhalers Live online/Classroom training

28-29 Jun 2022

Live online

09:00-17:30 UK (London) (UTC+01)
10:00-18:30 Paris (UTC+02)
04:00-12:30 New York (UTC-04)
Course code 11864

  • GBP 1,299 1,499
  • EUR 1,819 2,099
  • USD 2,026 2,338

Until 24 May

View basket 

14-15 Dec 2022

Classroom
London venue TBC

09:00-17:30 UK (London)
Course code 11667

  • GBP 1,299 1,499
  • EUR 1,819 2,099
  • USD 2,026 2,338

Until 09 Nov

  • 2 days classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

Reviews of IPI's Dry Powder Inhalers training course


Thanks all of them, they share their valuable experience. All of the speakers are valuable people, they are the best in their jobs. Conference met my expectation.

Jun 20 2018

Emre Kisasoz
Arven

Jun 20 2018

Well selected speakers, covering broad range.

Steffen Fredersdorf
Manager Clinical Program, Philip Morris International

Jun 20 2018

Very good organisation, time keeping, very valuable information delivered by speakers.

Waldemar Wiśniewski
Project Manager, Pulinno sp. z o.o.

Jun 20 2018

Interesting, helpful, nice examples, informative! Offers good overview on DPI's. Many thanks!

Ina Brueckner
CMC Manager Medical Devices, Bayer Pharma AG

Jun 27 2017

One of the best courses I attended

Anna Giulia Balducci
Senior Scientist, Chiesi Limited

Jun 27 2017

Overall I thought that the course was very useful, mainly due to the networking opportunities. The breadth of attendees was great to get wider conversations underway and broaden understanding. The scientific talks were generally excellent, and although some other talks were more around promoting products / services, the overall impression was positive and useful.

Richard Poole
Team Leader - Pharmaceutical Development, Vectura

Jun 27 2017

Very useful and relevant discussions

David Ward
Senior Formulation Scientist, Intertek

Jun 27 2017

In general, the course was very interesting and well organized

Berta Fernández Mollar
Senior Formulation Development Manager , Ferrer Internacional S. A.

Jun 27 2017

I really thought it as well organised with good content, length of presentations and quality of speakers.

Mahmoud Farag
Scientific Business Development Manager, Qualicaps

Jun 16 2016

Great environment to stimulate debate! And challenge preconceptions and novel ideas

Richard Turner
Director Global Sales, Presspart Manufacturing Ltd

Jun 16 2016

The course contained a good mix of speakers, the talks were current and relevant, the speakers responded well to lively discussions and challenges from the delegates. This is a good size meeting with questions freely asked and delegate interaction very high.

Tanya Church
Head of Laboratory, Chiesi Limited

Jun 16 2016

Very good and useful update. Clear messages coming through.

Simon Strothers
Director, 3P Innovation Ltd

Jun 16 2016

The course was very well organised, with a good selection of speakers and topics covered. I will certainly recommend future events to my colleagues.

Christopher Vernall
Business Development Director, Intertek Melbourn

UK

  • 3M Health Care Ltd
  • 3M Healthcare Ltd
  • 3P Innovation Limited
  • 3P Innovation Ltd
  • 42 Technology Ltd
  • Advanex Europe Ltd
  • Almac Group
  • Aptuit (Edinburgh) Ltd
  • Arven
  • ASTECH PROJECTS LTD
  • Aston Particle Technologies
  • AstraZeneca R&D Charnwood
  • Ballington Hall Associates
  • Bespak Europe Ltd
  • Bio Products Laboratory
  • BORCULO DOMO INGREDIENTS UK LTD
  • Britannia Pharmaceuticals Ltd
  • Cambridge Consultants Ltd
  • Cambridge Design Partnership
  • CARDINAL HEALTH
  • Catalent Pharma Solutions
  • CELLTECH
  • Chiesi
  • Chiesi Limited
  • Clariant Plastics & Coatings UK
  • Coalesce Product Development
  • Coalesce Product Development Ltd
  • Copley Scientific Limited
  • Crystec Ltd
  • DCA Design International
  • DCA Design International Ltd
  • DMV Fonterra Excipients
  • European Medicines Agency
  • Evoctec Oai Ltd
  • Exco InTouch Ltd
  • Gee-Whiz Associates
  • GlaxoSmith Kline
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals Europe R&F Ltd
  • Harro Hoefliger Packaging Systems Ltd
  • Hospira UK Limited
  • Ineos Fluor Ltd
  • INNOVATA BIOMED LIMITED
  • Innovata Ltd (part of Vectura Group plc)
  • Innovata plc
  • Insite Technology Limited
  • Intertek
  • Intertek Melbourn
  • Kings College London
  • Kinneir Dufort Ltd
  • Komax Group Ltd
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Merck Pharmaceuticals Limited
  • MHRA
  • Micron Technologies Ltd
  • Mills & Reeve LLP
  • MINISTRY OF DEFENCE
  • Molins Technologies
  • Monash University
  • Mundipharma Research Ltd
  • Mylan
  • Mylan Pharma UK Ltd
  • Nanopharm
  • Napp Pharmaceutical Group Ltd
  • NDA Regulatory Science Ltd
  • Novartis Pharmaceuticals UK Ltd
  • NYPRO EUROPE
  • Nypro Healthcare
  • OnDrugDelivery Ltd
  • Owen Mumford Ltd
  • PA Consulting
  • PA Consulting Group
  • PDL GROUP
  • PERLOS LTD
  • PFIZER GLOBAL R&D
  • PFIZER LIMITED
  • Pfizer Ltd
  • Presspart Manufacturing Limited
  • Presspart Manufacturing Ltd
  • Proveris Scientific
  • Quadrant Healthcare UK Plc
  • QUINTILES LTD
  • Quotient Clinical Ltd
  • Ranbaxy Laboratories Ltd
  • Respivert Ltd
  • RTS LIFE SCIENCE INTERNATIONAL
  • Sagentia Limited
  • Sandoz Limited
  • Sanoffi Aventis Ltd
  • Sanofi-Aventis
  • Scielutions Ltd
  • Springboard
  • Steve Harris Associates
  • Sympatec Limited
  • Team Consulting
  • Team Consulting Ltd
  • Technology Partnership Plc
  • Teva
  • Teva Pharmaceuticals
  • Teva UK Limited
  • Ticona UK Ltd
  • Trig1 Ltd
  • University of Bath
  • University of Warwick
  • Vectura
  • Vectura Group Plc
  • VECTURA LIMITED
  • Vectura Ltd

Germany

  • AEROPHARM GmbH
  • Alfred E Tiefenbacher GmbH & Co KG
  • Almirall Sofotec GmbH
  • BALDA MEDICAL GMBH
  • Bayer Healthcare AG
  • Bayer Pharma AG
  • Bayer Pharma AS
  • Berlin-Chemie AG
  • BfArM
  • Bitop AG
  • Boehringer Ingelheim Animal Health GmbH
  • Boehringer Ingelheim microParts GmbH
  • Boehringer Ingelheim Pharma GmbH & Co KG
  • BOVIMED GmbH
  • DFE Pharma
  • Federal Institut for Drug and Medical Devices
  • Fraunhofer ITEM
  • Gerresheimer Regensburg GmbH
  • GlaxoSmithKline GmbH & Co. KG
  • Grunenthal GmbH
  • Harro Hoefliger Verpackungsmaschinen GmbH
  • Harro Höfliger Verpackungsmaschinen GmbH
  • Helm AG
  • Hexal AG
  • IG SPRUHTECHNIK GmbH & CO KG
  • IMS HEALTH
  • KYORIN EUROPE GMBH
  • MEDA Pharam GmbH & Co KG
  • Molkerei MEGGLE Wasserburg GmbH & Co KG
  • Mundipharma Research GmbH & Co Kg
  • Optima Group pharma
  • Pari GmbH
  • Pharmazeutisches Institut der Universiat Kiel
  • Phillips-Medisize
  • Ratiopharm GmbH
  • RAUMEDIC AG
  • Revotar Biopharmaceuticals AG
  • Rexam Pharma GmbH
  • Robert Bosch GmbH
  • Robert Bosch Packaging Technology GmbH
  • RPC Formatec GmbH
  • Sandoz International GmbH
  • SARTORIUS AG
  • Siegfried Pharma Development GmbH
  • SOFOTEC GmbH & Co KG
  • Sortimat Assembly & Feeder Technology
  • STADA Arzneimittel AG
  • STEAG MICROPARTS GmbH
  • Styrolution Koln GmbH
  • Takeda GmbH
  • University of Kiel
  • Zentiva Inhalationsprodukte GmbH

United States of America

  • Actavis Inc
  • Aktiv-Dry LLC
  • BATTELLE MEMORIAL INSTITUTE
  • Breathe Pharmaceuticals
  • Cardinal Health
  • Catalent Pharma Solutions
  • CSP Technologies
  • EPIC THERA/MCKINNEY CONSULTING
  • EPIC THERAPEUTICS INC.
  • IMS Health
  • MannKind Corporation
  • NEKTAR THERAPEUTICS Inc
  • Next Breath
  • Nypro Healthcare
  • Pulmaxtix
  • ROXANE LABS INC
  • SAI HEALTHCARE
  • University of New Mexico
  • WEST PHARMACEUTICAL SERVICES

Switzerland

  • Actelion Pharmaceutical Ltd
  • Baumann Springs Ltd
  • Baumann Springs Ltd.
  • F. Hoffmann-La Roche Ltd
  • Forteq Healthcare
  • IBSA, Institut Biochimique SA
  • Komax Systems LCF SA
  • Merck Serono SA
  • Mikron SA Boudry
  • Novartis Pharma AG
  • Novartis Vaccines & Diagnostics AG
  • Philip Morris International
  • Phillips-Medisize
  • RCC LTD
  • RIWISA AG
  • Siegfried Ltd
  • SkyePharma AG

France

  • Aptar France
  • Aptar France SAS
  • APTAR FRANCE SAS (VALOIS SAS)
  • Aptar Pharma
  • Astrazeneca
  • BIOGEN IDEC FRANCE SA
  • Capsugel - France
  • CPI BIOCORP
  • CSP Technologies
  • Faculte des Sciences Pharmaceutiques et Biologiques
  • GlaxoWellcome Production
  • Nemera Services
  • Rexam Healthcare La Verpilliere
  • SANOFI AVENTIS R & D

Spain

  • Almirall S.A.
  • AstraZeneca
  • Chemo Group
  • Farmaprojects S.A.
  • Ferrer Internacional S. A.
  • Industrias Farmaceuticas Almiral S.A.
  • INSUD Pharma (Chemo)
  • INTAS THIRD PARTY SALES 2005 SL
  • Laboratorios Almirall S A
  • Laboratorios CINFA SA
  • Laboratorios Linconsa S.A.
  • LICONSA
  • Qualicaps
  • Qualicaps Europe SAU

Sweden

  • Astra Zeneca AB
  • AstraZeneca
  • AstraZeneca AB
  • CENSDELIVERY
  • Iconovo
  • Iconovo AB
  • Nolato Medical Business Area
  • Recipharm AB
  • Recipharm AB (publ)
  • Recipharm Publ Ab
  • XSpray Microparticles AB

Netherlands

  • Celanese Emulsions BV
  • Dishman Netherlands BV
  • FRIESLAND FOODS DOMO
  • IGS Gebojagema
  • PCH Pharmachemie B.V.
  • Pharmachemie BV
  • TEVA EUROPE/PHARMACHEMIE BV
  • Unilever R&D Vlaardingen
  • University of Groningen

Finland

  • Borealis Polymers Oy
  • LAB PHARMA OY
  • Orion Corporation
  • Orion Corporation Orion Pharma
  • Orion Oyj
  • Orion Pharma
  • Oy Medfiles Ltd
  • Phillips-Medisize

Italy

  • Chiesi Farmaceutici S.p.A.
  • Chiesi Farmaceutici SPA
  • MIAT SpA
  • PH&T SpA
  • Plastiape SpA
  • University of Parma
  • Zambon Group SpA

Denmark

  • Bang & Olufsen Medicom a/s
  • Bang & Olufsen Medicom AS
  • DIRECT-HALER AS
  • Ferring Pharmaceuticals A/S
  • FERROSAN A/S
  • Novo Nordisk A/S

Poland

  • CBR Novasome Sp Z.o.o.
  • Passio Group
  • Polpharma SA
  • Pulinno
  • Pulinno sp. z o.o.
  • Zakład Farmaceutyczny Adamed Pharma SA

Ireland

  • Nypro Healthcare
  • PFIZER IRELAND PHARMACEUTICALS
  • TECH GROUP
  • Tech Group Europe
  • Teva Pharmaceuticals Ireland

Israel

  • Aespira Ltd
  • Inspiro Medical
  • Kamada Ltd
  • Teva Pharmaceutical Industries Ltd

Portugal

  • Hovione Capital
  • Hovione Farmaciência S.A.
  • Hovione Farmaciencia Sa
  • Tecnimede S.A.

Belgium

  • Capsugel
  • IMS HEALTH
  • Laboratoires SMB S.A.

Turkey

  • DEVA HOLDING A.S
  • Neutec Inhaler San. Tic. A.S.
  • Sanovel Pharmaceutical INC

India

  • Aarti Industries Ltd
  • CIPLA LTD

Argentina

  • Laboratorio Dosa SA

Australia

  • Pharmaxis Ltd

Brazil

  • Job Consultoria

Canada

  • MERCK FROSST CANADA LIMITED

Cyprus

  • Medochemie Limited

Egypt

  • Delta Pharma

Greece

  • ELPEN Pharmaceutical Co Inc

Japan

  • Qualicaps

New Zealand

  • Nexus6

Russia

  • Pharmaceutical Factory of Saint-Petersburg

Saudi Arabia

  • Cad Middle East Pharmaceutical Industries

Enrol now

Multiple colleagues?
Talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra BEER
Training expert

+44 (0)20 7749 4749

inhouse@ipi.academy